IRWD News and Press, Ironwood Pharmaceuticals Inc. From 06/12/23

2023-06-12 09:54:54 ET Despite having a successful drug on the market and making a major acquisition recently, share prices of Ironwood Pharmaceuticals (NASDAQ: IRWD) are down by 7% this year so far. Wall Street analysts take a gloomy view of its future, with average estimates calli...

2023-05-22 17:43:00 ET Ironwood Pharmaceuticals (NASDAQ: IRWD) is choosing to go the acquisition route to grow its business. On Monday, the company announced it has agreed to acquire clinical-stage biotech VectivBio Holding (NASDAQ: VECT) . Investors were clearly warm to tha...

2023-05-22 12:02:21 ET Shares of VectivBio Holdings (NASDAQ: VECT) were up more than 35% Monday morning after the clinical-stage biotech company received a buyout offer from Ironwood Pharmaceuticals (NASDAQ: IRWD) . VectivBio's shares are up more than 85% so far this...

2023-05-22 07:22:48 ET Ironwood Pharmaceuticals ( NASDAQ: IRWD ) fell ~15% in the pre-market Monday after the company focused on gastrointestinal (GI) products agreed to acquire the Swiss biotech VectivBio Holding AG ( NASDAQ: VECT ) for $17.00 per share in an all-cash...

- Transaction Advances Ironwood’s Vision of Becoming the Leading GI Healthcare Company - - Adds apraglutide, Next Generation, Synthetic GLP-2 Analog in Phase 3 for Short Bowel Syndrome with Intestinal Failure (SBS-IF); Potential to become Best-in-Class for SBS-IF - - Orphan...

2023-05-22 05:00:00 ET Summary Pharmaceuticals/biotechnology and healthcare providers still have good value scores. Healthcare equipment is the less attractive subsector. Fast facts on IHF, a healthcare providers ETF. 10 stocks cheaper than their peers in May. ...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 1:30 p.m. ET at the New York Hilton Midtown. A live audio webcast of Ironwood’s fireside chat w...

– Additional data presentations further characterize the efficacy and safety profiles of linaclotide in this patient population – – Functional constipation affects an estimated 6 million 6-17 year-olds in the U.S. 1 ­; there are currently no FDA-approved pres...

2023-05-06 18:23:09 ET Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2023 Results Conference Call May 04, 2023 08:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - CEO Mike Shetzline - Chief Medical Officer Sravan Emany - Chi...

2023-05-04 07:16:41 ET Ironwood Pharmaceuticals press release ( NASDAQ: IRWD ): Q1 Non-GAAP EPS of $0.25 beats by $0.01 . Revenue of $104.06M (+6.7% Y/Y) beats by $3.46M . 2023 Guidance: U.S. LINZESS Net Sales Growth 3% to 5%, Total Revenue $420 t...